What Do German Molecular Tumor Boards Recommend in Patients with PIK3CA-Mutated Tumors? Launch and First Results from the German Transsectoral Molecular Tumor Board Exchange Platform Deutschland.

IF 2 4区医学 Q3 ONCOLOGY

Oncology Research and Treatment Pub Date : 2024-01-01 Epub Date: 2024-05-07 DOI:10.1159/000539217

Ina Pretzell, Alexander Desuki, Annalen Bleckmann, Sonja Loges, Anke Reinacher-Schick, C Benedikt Westphalen, Sebastian Lange

{"title":"What Do German Molecular Tumor Boards Recommend in Patients with PIK3CA-Mutated Tumors? Launch and First Results from the German Transsectoral Molecular Tumor Board Exchange Platform Deutschland.","authors":"Ina Pretzell, Alexander Desuki, Annalen Bleckmann, Sonja Loges, Anke Reinacher-Schick, C Benedikt Westphalen, Sebastian Lange","doi":"10.1159/000539217","DOIUrl":null,"url":null,"abstract":"Introduction: Comprehensive molecular tumor profiling is widely used in the management of patients with cancer. Molecular tumor boards devise treatment strategies based on testing results. In this setting, the Transsectoral Molecular Tumor Board exchange platform Deutschland (TEAM-D) aims to drive peer-to-peer exchange to connect experts in the field.Methods: During the first virtual TEAM-D meeting, participants from 16 German universities and 5 nonacademic institutions discussed five cases with PIK3CA hotspot mutations. Furthermore, an illustrative case vignette was presented.Results: Overall, German caregivers show restraint in administering off-label PIK3CA inhibitor and favor clinical trials in this setting.Conclusion: In the setting of precision oncology, TEAM-D enables virtual case discussion across the different sectors of the German healthcare system. Based on the example of PIK3CA hotspot mutations, TEAM-D demonstrated the value of integrating knowledge from different healthcare professionals.","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"410-419"},"PeriodicalIF":2.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology Research and Treatment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000539217","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/7 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Comprehensive molecular tumor profiling is widely used in the management of patients with cancer. Molecular tumor boards devise treatment strategies based on testing results. In this setting, the Transsectoral Molecular Tumor Board exchange platform Deutschland (TEAM-D) aims to drive peer-to-peer exchange to connect experts in the field.

Methods: During the first virtual TEAM-D meeting, participants from 16 German universities and 5 nonacademic institutions discussed five cases with PIK3CA hotspot mutations. Furthermore, an illustrative case vignette was presented.

Results: Overall, German caregivers show restraint in administering off-label PIK3CA inhibitor and favor clinical trials in this setting.

Conclusion: In the setting of precision oncology, TEAM-D enables virtual case discussion across the different sectors of the German healthcare system. Based on the example of PIK3CA hotspot mutations, TEAM-D demonstrated the value of integrating knowledge from different healthcare professionals.

查看原文本刊更多论文

德国分子肿瘤委员会对 PIK3CA 突变肿瘤患者有何建议？- 德国TEAM-D跨部门分子肿瘤委员会交流平台（TEAM-D）的启动和首批成果。

背景和原理：全面的肿瘤分子图谱分析被广泛用于癌症患者的治疗。分子肿瘤委员会根据检测结果制定治疗策略。在此背景下，跨部门分子肿瘤委员会交流平台德国（TEAM-D）旨在推动同行交流，将该领域的专家联系起来：在第一次 TEAM-D 虚拟会议期间，来自 16 所德国大学和 5 个非学术机构的与会者讨论了五例 PIK3CA 热点突变病例。此外，还介绍了一个说明性病例小故事：总体而言，德国护理人员在使用标签外 PIK3CA 抑制剂时表现出克制，并赞成在这种情况下进行临床试验：结论：在精准肿瘤学领域，TEAM-D 可以在德国医疗保健系统的不同部门之间进行虚拟病例讨论。以 PIK3CA 热点突变为例，TEAM-D 展示了整合不同医疗保健专业人员知识的价值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncology Research and Treatment ONCOLOGY-

CiteScore

3.20

自引率

0.00%

发文量

期刊介绍： With the first issue in 2014, the journal ''Onkologie'' has changed its title to ''Oncology Research and Treatment''. By this change, publisher and editor set the scene for the further development of this interdisciplinary journal. The English title makes it clear that the articles are published in English – a logical step for the journal, which is listed in all relevant international databases. For excellent manuscripts, a ''Fast Track'' was introduced: The review is carried out within 2 weeks; after acceptance the papers are published online within 14 days and immediately released as ''Editor’s Choice'' to provide the authors with maximum visibility of their results. Interesting case reports are published in the section ''Novel Insights from Clinical Practice'' which clearly highlights the scientific advances which the report presents.